LivaNova (NSDQ:LIVN) said recently that it is ending its Caisson Interventional transcatheter mitral valve replacement (TMVR) program and plans to restructure its heart valve business to improve profitability.
The company’s heart valve business represented nearly $130 million in revenue during fiscal 2018 and saw its revenue numbers decline over the last five years, both with biological and mechanical valves, leading to a decision to begin restructuring, according to a news release.
Get the full story on our sister site, MassDevice.